Research ExplorerPublicationsAntigen-specific tolerance by autologous myelin peptide-coup...

Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis

Standard

Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. / Lutterotti, Andreas; Yousef, Sara; Sputtek, Andreas; Stürner, Klarissa H; Stellmann, Jan-Patrick; Breiden, Petra; Reinhardt, Stefanie; Schulze, Christian; Bester, Maxim; Heesen, Christoph; Schippling, Sven; Miller, Stephen D; Sospedra, Mireia; Martin, Roland.

In: SCI TRANSL MED, Vol. 5, No. 188, 05.06.2013, p. 188ra75.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lutterotti, A, Yousef, S, Sputtek, A, Stürner, KH, Stellmann, J-P, Breiden, P, Reinhardt, S, Schulze, C, Bester, M, Heesen, C, Schippling, S, Miller, SD, Sospedra, M & Martin, R 2013, 'Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis', SCI TRANSL MED, vol. 5, no. 188, pp. 188ra75. https://doi.org/10.1126/scitranslmed.3006168

APA

Lutterotti, A., Yousef, S., Sputtek, A., Stürner, K. H., Stellmann, J-P., Breiden, P., Reinhardt, S., Schulze, C., Bester, M., Heesen, C., Schippling, S., Miller, S. D., Sospedra, M., & Martin, R. (2013). Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. SCI TRANSL MED, 5(188), 188ra75. https://doi.org/10.1126/scitranslmed.3006168

Vancouver

Lutterotti A, Yousef S, Sputtek A, Stürner KH, Stellmann J-P, Breiden P et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. SCI TRANSL MED. 2013 Jun 5;5(188):188ra75. https://doi.org/10.1126/scitranslmed.3006168

Bibtex

@article{a587f6471780488e98d9fb5635fd8f10,
title = "Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis",
abstract = "Multiple sclerosis (MS) is a devastating inflammatory disease of the brain and spinal cord that is thought to result from an autoimmune attack directed against antigens in the central nervous system. The aim of this first-in-man trial was to assess the feasibility, safety, and tolerability of a tolerization regimen in MS patients that uses a single infusion of autologous peripheral blood mononuclear cells chemically coupled with seven myelin peptides (MOG1-20, MOG35-55, MBP13-32, MBP83-99, MBP111-129, MBP146-170, and PLP139-154). An open-label, single-center, dose-escalation study was performed in seven relapsing-remitting and two secondary progressive MS patients who were off-treatment for standard therapies. All patients had to show T cell reactivity against at least one of the myelin peptides used in the trial. Neurological, magnetic resonance imaging, laboratory, and immunological examinations were performed to assess the safety, tolerability, and in vivo mechanisms of action of this regimen. Administration of antigen-coupled cells was feasible, had a favorable safety profile, and was well tolerated in MS patients. Patients receiving the higher doses (>1 × 10(9)) of peptide-coupled cells had a decrease in antigen-specific T cell responses after peptide-coupled cell therapy. In summary, this first-in-man clinical trial of autologous peptide-coupled cells in MS patients establishes the feasibility and indicates good tolerability and safety of this therapeutic approach.",
keywords = "Adolescent, Adult, Blood Cell Count, Demography, Disease Progression, Epitopes, Female, Humans, Immune Tolerance, Leukocytes, Mononuclear, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Myelin Sheath, Peptides, Young Adult",
author = "Andreas Lutterotti and Sara Yousef and Andreas Sputtek and St{\"u}rner, {Klarissa H} and Jan-Patrick Stellmann and Petra Breiden and Stefanie Reinhardt and Christian Schulze and Maxim Bester and Christoph Heesen and Sven Schippling and Miller, {Stephen D} and Mireia Sospedra and Roland Martin",
year = "2013",
month = jun,
day = "5",
doi = "10.1126/scitranslmed.3006168",
language = "English",
volume = "5",
pages = "188ra75",
journal = "SCI TRANSL MED",
issn = "1946-6234",
publisher = "AMER ASSOC ADVANCEMENT SCIENCE",
number = "188",

}

RIS

TY - JOUR

T1 - Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis

AU - Lutterotti, Andreas

AU - Yousef, Sara

AU - Sputtek, Andreas

AU - Stürner, Klarissa H

AU - Stellmann, Jan-Patrick

AU - Breiden, Petra

AU - Reinhardt, Stefanie

AU - Schulze, Christian

AU - Bester, Maxim

AU - Heesen, Christoph

AU - Schippling, Sven

AU - Miller, Stephen D

AU - Sospedra, Mireia

AU - Martin, Roland

PY - 2013/6/5

Y1 - 2013/6/5

N2 - Multiple sclerosis (MS) is a devastating inflammatory disease of the brain and spinal cord that is thought to result from an autoimmune attack directed against antigens in the central nervous system. The aim of this first-in-man trial was to assess the feasibility, safety, and tolerability of a tolerization regimen in MS patients that uses a single infusion of autologous peripheral blood mononuclear cells chemically coupled with seven myelin peptides (MOG1-20, MOG35-55, MBP13-32, MBP83-99, MBP111-129, MBP146-170, and PLP139-154). An open-label, single-center, dose-escalation study was performed in seven relapsing-remitting and two secondary progressive MS patients who were off-treatment for standard therapies. All patients had to show T cell reactivity against at least one of the myelin peptides used in the trial. Neurological, magnetic resonance imaging, laboratory, and immunological examinations were performed to assess the safety, tolerability, and in vivo mechanisms of action of this regimen. Administration of antigen-coupled cells was feasible, had a favorable safety profile, and was well tolerated in MS patients. Patients receiving the higher doses (>1 × 10(9)) of peptide-coupled cells had a decrease in antigen-specific T cell responses after peptide-coupled cell therapy. In summary, this first-in-man clinical trial of autologous peptide-coupled cells in MS patients establishes the feasibility and indicates good tolerability and safety of this therapeutic approach.

AB - Multiple sclerosis (MS) is a devastating inflammatory disease of the brain and spinal cord that is thought to result from an autoimmune attack directed against antigens in the central nervous system. The aim of this first-in-man trial was to assess the feasibility, safety, and tolerability of a tolerization regimen in MS patients that uses a single infusion of autologous peripheral blood mononuclear cells chemically coupled with seven myelin peptides (MOG1-20, MOG35-55, MBP13-32, MBP83-99, MBP111-129, MBP146-170, and PLP139-154). An open-label, single-center, dose-escalation study was performed in seven relapsing-remitting and two secondary progressive MS patients who were off-treatment for standard therapies. All patients had to show T cell reactivity against at least one of the myelin peptides used in the trial. Neurological, magnetic resonance imaging, laboratory, and immunological examinations were performed to assess the safety, tolerability, and in vivo mechanisms of action of this regimen. Administration of antigen-coupled cells was feasible, had a favorable safety profile, and was well tolerated in MS patients. Patients receiving the higher doses (>1 × 10(9)) of peptide-coupled cells had a decrease in antigen-specific T cell responses after peptide-coupled cell therapy. In summary, this first-in-man clinical trial of autologous peptide-coupled cells in MS patients establishes the feasibility and indicates good tolerability and safety of this therapeutic approach.

KW - Adolescent

KW - Adult

KW - Blood Cell Count

KW - Demography

KW - Disease Progression

KW - Epitopes

KW - Female

KW - Humans

KW - Immune Tolerance

KW - Leukocytes, Mononuclear

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis

KW - Myelin Sheath

KW - Peptides

KW - Young Adult

U2 - 10.1126/scitranslmed.3006168

DO - 10.1126/scitranslmed.3006168

M3 - SCORING: Journal article

C2 - 23740901

VL - 5

SP - 188ra75

JO - SCI TRANSL MED

JF - SCI TRANSL MED

SN - 1946-6234

IS - 188

ER -